Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

AbbVie700 enrolled

Overview

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL. Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally. Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Study Type

OBSERVATIONAL

Enrollment

700

Conditions

Diffuse Large B-cell Lymphoma Follicular Lymphoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL). * Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country. * The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study. Exclusion Criteria: * Any condition included in the contraindications section of the approved local epcoritamab label in the participating country. * Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.

Locations (73)

Hospital Britanico de Buenos Aires /ID# 274419

Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

RECRUITING

Hospital Universitario Austral /ID# 274393

Pilar, Buenos Aires, Argentina

RECRUITING

Instituto Alexander Fleming /ID# 277284

Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina

RECRUITING

Hospital Privado Universitario De Córdoba /ID# 274457

Córdoba, Córdoba Province, Argentina

Outcomes

Primary Outcomes

Percentage of Participants Achieving Overall Response (OR)

Defined as the percentage of participants who achieve best overall response of complete response (CR) or partial response (PR) determined by Lugano criteria

Time frame: Up to approximately 3 years

Central Contacts

Rebekah Taylor

CONTACT

(847) 937-8000 rebekah.taylor@abbvie.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Hospital Italiano de Buenos Aires /ID# 274418

Buenos Aires, Argentina

RECRUITING

Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390

Buenos Aires, Argentina

RECRUITING

Nepean Cancer Centre, Nepean Hospital /ID# 277782

Kingswood, New South Wales, Australia

RECRUITING

Calvary Mater Newcastle /ID# 277783

Waratah, New South Wales, Australia

RECRUITING

Cabrini Hospital Malvern /ID# 277780

Malvern, Victoria, Australia

RECRUITING

Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288

Graz, Styria, Austria

RECRUITING

...and 63 more locations